AbCellera Biologics Inc. Common Shares
Here’s whether AbCellera Biologics Inc. Common Shares (ABCL) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+16.49% over 10 days); strong 1-year return of +163.3%; 3-month momentum positive (+117.7%); rising volume confirms the move (1.80x 30d avg). Concerns: RSI 86 — overbought, elevated pullback risk. Currently 6.8% off its 52-week high. Score: +6/7.
ABCL is in a confirmed uptrend, trading above both its 50-day ($7.21) and 200-day ($4.76) moving averages. With an RSI of 85.5, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +163.3% compares to +20.5% for SPY (beat the market by 142.8%).